Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Low Grade B-cell Lymphoma Not Otherwise Specified
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Peripheral T-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Clofarabine (clofarabine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-08